Highland Therapeutics to Present at Piper Jaffray Healthcare Conference

TORONTO--()--Highland Therapeutics Inc. (“Highland”), a pharmaceutical company, today announced that the Company will present at the 27th Annual Piper Jaffray Healthcare Conference at the New York Palace Hotel in New York City. Highland’s presentation is scheduled for Tuesday, December 1, 2015 at 2:30pm EST.

Highland will provide the investment community with an overview of the Company, as well as an update on recent corporate developments, including for HLD-200 – its lead program currently in pivotal trials for the treatment of ADHD, and for its pipeline program, HLD-900 – in development for the treatment of binge eating disorder. A pivotal trial for HLD-900 is anticipated to begin in 2016.

About HLD-200

HLD-200 is a novel, delayed-release, extended-release formulation of methylphenidate based on Ironshore Pharmaceuticals & Development, Inc.’s proprietary DELEXIS® technology. HLD-200 is designed to be taken once-daily in the evening with the objective of controlling symptoms and improving functioning in ADHD patients immediately upon awakening and throughout the day. An exploratory Phase III study was successfully completed in pediatric ADHD patients in 2014. Two pivotal Phase III studies are ongoing, with top-line data anticipated in the first quarter of 2016.

About Highland Therapeutics Inc.

Highland Therapeutics Inc. is a pharmaceutical company that, through its wholly owned subsidiary Ironshore Pharmaceuticals & Development, Inc., is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products. The Company’s lead product candidates, HLD-200 and HLD-100, are novel formulations of the psychostimulants (methylphenidate and amphetamine, respectively) used to treat ADHD and are being developed to address a prevalent unmet medical need in the treatment of the disease – inadequate symptom control during the morning routine. Intended for nighttime dosing, DELEXIS® is designed to provide a consistent delay in the initial release of the active drug, followed by a period of extended release; with the objective of providing control of ADHD symptoms immediately upon wakening and throughout the day.

Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.

For further information, please visit the Company’s website at www.highlandtherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking information, which reflects Highland’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Highland’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Highland assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

Highland Therapeutics Inc.
Nelson F. Isabel, 647-260-7875
Chief Financial Officer

Contacts

Highland Therapeutics Inc.
Nelson F. Isabel, 647-260-7875
Chief Financial Officer